Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company listed on the NASDAQ under the symbol TSHA. The company is focused on developing and commercializing adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous system. Its pipeline includes TSHA-120 for giant axonal neuropathy, TSHA-102 for Rett syndrome, TSHA-121 for CLN7 disease, TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 deficiency, TSHA-113 for tauopathies, TSHA-106 for Angelman syndrome, and TSHA-114 for fragile X syndrome. Taysha also has a research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. The company was incorporated in 2019 and is based in Dallas, Texas.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TSHA
|
$4.57
|
-20.1% Downside
|
Overvalued
|
$13.15
|
130.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-14.2x
|
8.7x
|
246.4x
|
1.785 B
|
1.633 B
|
3.7%
|
71.7%
|
8.2
|
—
|
86.5%
|
